Janney Montgomery Scott LLC Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Janney Montgomery Scott LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 23,066 shares of the biopharmaceutical company’s stock after purchasing an additional 4,130 shares during the period. Janney Montgomery Scott LLC’s holdings in Regeneron Pharmaceuticals were worth $16,431,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at about $37,000. Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $49,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $675.79 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $727.19 and a 200-day moving average of $937.77. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The firm has a market cap of $74.26 billion, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Bank of America restated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Sanford C. Bernstein lowered their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.